Gossamer Bio公布Seralutinib治疗肺动脉高压的III期Prosera研究顶线结果

美股速递02-23

Gossamer Bio Inc. (股票代码：GOSS) 近日披露了其III期临床试验Prosera研究的顶线数据。该研究旨在评估候选药物Seralutinib在肺动脉高压患者中的疗效与安全性。

这项关键性研究的结果标志着公司在肺动脉高压治疗领域的重要进展。顶线数据的公布为后续研发决策提供了关键依据，也将影响该药物的上市申请策略。

肺动脉高压作为一种罕见且严重的疾病，目前仍存在未满足的临床需求。Seralutinib若最终获批，有望为患者提供新的治疗选择。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1131316037?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-23 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131316037","market":"us","top_or_hot":-1,"title":"Gossamer Bio公布Seralutinib治疗肺动脉高压的III期Prosera研究顶线结果","media":"美股速递","content":"<p>Gossamer Bio Inc. (股票代码：GOSS) 近日披露了其III期临床试验Prosera研究的顶线数据。该研究旨在评估候选药物Seralutinib在肺动脉高压患者中的疗效与安全性。</p>\n<p>这项关键性研究的结果标志着公司在肺动脉高压治疗领域的重要进展。顶线数据的公布为后续研发决策提供了关键依据，也将影响该药物的上市申请策略。</p>\n<p>肺动脉高压作为一种罕见且严重的疾病，目前仍存在未满足的临床需求。Seralutinib若最终获批，有望为患者提供新的治疗选择。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gossamer Bio公布Seralutinib治疗肺动脉高压的III期Prosera研究顶线结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGossamer Bio公布Seralutinib治疗肺动脉高压的III期Prosera研究顶线结果\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-23 21:05 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gossamer Bio Inc. (股票代码：GOSS) 近日披露了其III期临床试验Prosera研究的顶线数据。该研究旨在评估候选药物Seralutinib在肺动脉高压患者中的疗效与安全性。\n这项关键性研究的结果标志着公司在肺动脉高压治疗领域的重要进展。顶线数据的公布为后续研发决策提供了关键依据，也将影响该药物的上市申请策略。\n肺动脉高压作为一种罕见且严重的疾病，目前仍存在未满足的临床需求。...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1131316037","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131316037","pubTimestamp":1771851937,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Gossamer Bio Inc. (股票代码：GOSS) 近日披露了其III期临床试验Prosera研究的顶线数据。该研究旨在评估候选药物Seralutinib在肺动脉高压患者中的疗效与安全性。\n这项关键性研究的结果标志着公司在肺动脉高压治疗领域的重要进展。顶线数据的公布为后续研发决策提供了关键依据，也将影响该药物的上市申请策略。\n肺动脉高压作为一种罕见且严重的疾病，目前仍存在未满足的临床需求。Seralutinib若最终获批，有望为患者提供新的治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","GOSS":"Gossamer Bio Inc.","BK4505":"高瓴资本持仓"},"translate_title":"Gossamer Bio Announces Top-Line Results of Phase III Prosera Study of Seralutinib in Pulmonary Hypertension","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GOSS":1},"content_text":"Gossamer Bio Inc. (股票代码：GOSS) 近日披露了其III期临床试验Prosera研究的顶线数据。该研究旨在评估候选药物Seralutinib在肺动脉高压患者中的疗效与安全性。\n这项关键性研究的结果标志着公司在肺动脉高压治疗领域的重要进展。顶线数据的公布为后续研发决策提供了关键依据，也将影响该药物的上市申请策略。\n肺动脉高压作为一种罕见且严重的疾病，目前仍存在未满足的临床需求。Seralutinib若最终获批，有望为患者提供新的治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131316037","isCrawlerRequest":true}